4.7 Review

Viral targets for vaccines against COVID-19

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Immunology

Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

Kai Wang et al.

Summary: This study found that specific neutralizing antibody titers against SARS-CoV-2 in patients with COVID-19 were initially low in the first 7-10 days after symptom onset, then gradually increased and peaked at 2-3 weeks. The titers of neutralizing antibodies and IgG levels showed a positive correlation over time, and were also significantly correlated with levels of proinflammatory cytokines.

CLINICAL INFECTIOUS DISEASES (2021)

Article Biochemistry & Molecular Biology

Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies

Meng Yuan et al.

Summary: Since the outbreak of COVID-19 pandemic, researchers from diverse biomedical and biological disciplines have collaborated to study the novel pandemic virus SARS-CoV-2. The focus has been on the antibody response to SARS-CoV-2, crucial for vaccine and therapeutic development. Most of the neutralizing antibodies for SARS-CoV-2 target the spike protein receptor binding domain (RBD).

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2021)

Editorial Material Pharmacology & Pharmacy

Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2

Shibo Jiang et al.

EXPERT OPINION ON THERAPEUTIC TARGETS (2021)

Article Infectious Diseases

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

Shengli Xia et al.

Summary: The inactivated SARS-CoV-2 vaccine, BBIBP-CorV, demonstrated safety and immunogenicity in two age groups. Humoral responses against SARS-CoV-2 were induced in all vaccine recipients by day 42. A two-dose immunisation with 4 mu g vaccine on days 0 and 21 or days 0 and 28 achieved higher neutralising antibody titres compared to other dosing schedules.

LANCET INFECTIOUS DISEASES (2021)

Review Microbiology

Learning from the past: development of safe and effective COVID-19 vaccines

Shan Su et al.

Summary: In the development of a COVID-19 vaccine, it is crucial to prioritize safety and efficacy evaluations, drawing lessons from past vaccine development efforts. Su, Du, and Jiang summarize the lessons from previous vaccine development for other viruses, highlighting how mechanisms of vaccine-associated disease enhancement can inform the development of a safe and effective COVID-19 vaccine.

NATURE REVIEWS MICROBIOLOGY (2021)

Article Immunology

Treatment of immunocompromised COVID-19 patients with convalescent plasma

Monica Fung et al.

Summary: Convalescent plasma treatment appears to be safe and potentially beneficial for immunosuppressed patients with COVID-19, as evidenced by clinical improvements in patients who received this therapy. Further data is needed to determine the efficacy of convalescent plasma as a primary or adjunctive therapy for COVID-19, especially for immunocompromised patients.

TRANSPLANT INFECTIOUS DISEASE (2021)

Article Medicine, General & Internal

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Peter Chen et al.

Summary: LY-CoV555, a neutralizing antibody, showed promising results in reducing viral load, improving symptoms, and lowering the risk of hospitalization among patients with mild or moderate Covid-19. While one of the doses appeared to accelerate the decline in viral load, others did not show significant effects by day 11.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Infectious Diseases

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Yanjun Zhang et al.

Summary: This study investigated the safety, tolerability, and immunogenicity of the COVID-19 vaccine candidate CoronaVac, and found that the 3 μg dose showed higher seroconversion rates in the phase 2 trial.

LANCET INFECTIOUS DISEASES (2021)

Article Immunology

Randomized, Double-Blinded, Placebo-Controlled Phase 2 Trial of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in Healthy Adults

Yanchun Che et al.

Summary: This study evaluated an inactivated SARS-CoV-2 vaccine for immunogenicity and safety in adults aged 18-59 years. The results showed that vaccinated adults developed neutralizing antibodies as well as anti-S/N antibodies with a low rate of adverse reactions.

CLINICAL INFECTIOUS DISEASES (2021)

Article Multidisciplinary Sciences

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Daniel Wrapp et al.

SCIENCE (2020)

Article Biochemistry & Molecular Biology

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Alexandra C. Walls et al.

Article Medicine, General & Internal

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Chenguang Shen et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Review Medicine, Research & Experimental

Deployment of convalescent plasma for the prevention and treatment of COVID-19

Evan M. Bloch et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

Article Multidisciplinary Sciences

Site-specific glycan analysis of the SARS-CoV-2 spike

Yasunori Watanabe et al.

SCIENCE (2020)

Editorial Material Multidisciplinary Sciences

Rapid COVID-19 vaccine development

Barney S. Graham

SCIENCE (2020)

Article Multidisciplinary Sciences

Development of an inactivated vaccine candidate for SARS-CoV-2

Qiang Gao et al.

SCIENCE (2020)

Article Multidisciplinary Sciences

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Jingyou Yu et al.

SCIENCE (2020)

Article Multidisciplinary Sciences

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Rui Shi et al.

NATURE (2020)

Article Multidisciplinary Sciences

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Bin Ju et al.

NATURE (2020)

Article Biochemistry & Molecular Biology

Antibody responses to SARS-CoV-2 in patients with COVID-19

Quan-Xin Long et al.

NATURE MEDICINE (2020)

Article Biochemistry & Molecular Biology

A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS

Lianpan Dai et al.

Article Biochemistry & Molecular Biology

A Thermostable mRNA Vaccine against COVID-19

Na-Na Zhang et al.

Review Immunology

Immunomodulatory Drugs in the Management of SARS-CoV-2

Daniel R. Burrage et al.

FRONTIERS IN IMMUNOLOGY (2020)

Article Medicine, General & Internal

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes Interim Analysis of 2 Randomized Clinical Trials

Shengli Xia et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Review Virology

COVID-19 Vaccines: Warp Speed Needs Mind Melds, Not Warped Minds

John P. Moore et al.

JOURNAL OF VIROLOGY (2020)

Article Biochemistry & Molecular Biology

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Takuya Sekine et al.

Article Multidisciplinary Sciences

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Julian Braun et al.

NATURE (2020)

Article Multidisciplinary Sciences

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

Noe B. Mercado et al.

NATURE (2020)

Article Multidisciplinary Sciences

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

Kizzmekia S. Corbett et al.

NATURE (2020)

Article Multidisciplinary Sciences

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

Neeltje van Doremalen et al.

NATURE (2020)

Article Multidisciplinary Sciences

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

Mark J. Mulligan et al.

NATURE (2020)

Article Multidisciplinary Sciences

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Davide F. Robbiani et al.

NATURE (2020)

Article Multidisciplinary Sciences

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Lihong Liu et al.

NATURE (2020)

Article Multidisciplinary Sciences

Potently neutralizing and protective human antibodies against SARS-CoV-2

Seth J. Zost et al.

NATURE (2020)

Article Medicine, General & Internal

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

Kizzmekia S. Corbett et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Medicine, General & Internal

An mRNA Vaccine against SARS-CoV-2-Preliminary Report

L. A. Jackson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Multidisciplinary Sciences

Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy

Hongjing Gu et al.

SCIENCE (2020)

Article Multidisciplinary Sciences

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Ching-Lin Hsieh et al.

SCIENCE (2020)

Article Multidisciplinary Sciences

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Johanna Hansen et al.

SCIENCE (2020)

Article Multidisciplinary Sciences

Distinct conformational states of SARS-CoV-2 spike protein

Yongfei Cai et al.

SCIENCE (2020)

Article Multidisciplinary Sciences

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Philip J. M. Brouwer et al.

SCIENCE (2020)

Article Multidisciplinary Sciences

Broad neutralization of SARS-related viruses by human monoclonal antibodies

Anna Z. Wec et al.

SCIENCE (2020)

Article Cell Biology

Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits

Supriya Ravichandran et al.

SCIENCE TRANSLATIONAL MEDICINE (2020)

Article Multidisciplinary Sciences

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Ugur Sahin et al.

NATURE (2020)

Article Biochemistry & Molecular Biology

Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters

Lisa H. Tostanoski et al.

NATURE MEDICINE (2020)

Article Medicine, General & Internal

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Medicine, General & Internal

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

E. J. Anderson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Medicine, General & Internal

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Cheryl Keech et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Multidisciplinary Sciences

Zika virus infection enhances future risk of severe dengue disease

Leah C. Katzelnick et al.

SCIENCE (2020)

Review Microbiology

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

Wen Shi Lee et al.

NATURE MICROBIOLOGY (2020)

News Item Medicine, General & Internal

Covid-19: UK approves Pfizer and BioNTech vaccine with rollout due to start next week

Elisabeth Mahase

BMJ-BRITISH MEDICAL JOURNAL (2020)

Article Multidisciplinary Sciences

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans

Kevin W. Ng et al.

SCIENCE (2020)

Review Immunology

Immunological considerations for COVID-19 vaccine strategies

Mangalakumari Jeyanathan et al.

NATURE REVIEWS IMMUNOLOGY (2020)

Review Biochemistry & Molecular Biology

The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design

Felix A. Rey et al.

EMBO REPORTS (2018)

Review Immunology

Native-like Env trimers as a platform for HIV-1 vaccine design

Rogier W. Sanders et al.

IMMUNOLOGICAL REVIEWS (2017)

Article Multidisciplinary Sciences

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

Jesper Pallesen et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)

Review Pharmacology & Pharmacy

T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV

William J. Liu et al.

ANTIVIRAL RESEARCH (2017)

Review Biochemistry & Molecular Biology

Bat-to-human: spike features determining 'host jump' of coronaviruses SARS-CoV, MERS-CoV, and beyond

Guangwen Lu et al.

TRENDS IN MICROBIOLOGY (2015)

Article Biochemistry & Molecular Biology

Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins

Sheng-Fan Wang et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)

Article Multidisciplinary Sciences

Rapid generation of a mouse model for Middle East respiratory syndrome

Jincun Zhao et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)

Article Biochemistry & Molecular Biology

Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R

William C. Hwang et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2006)

Article Biochemistry & Molecular Biology

Oligomerization of the SARS-CoV S glycoprotein: dimerization of the N-terminus and trimerization of the ectodomain

XD Xiao et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)

Article Biochemistry & Molecular Biology

Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine

YX He et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)

Article Fisheries

Cytotoxic T lymphocytes are critical in the control of infectious bronchitis virus in poultry

EW Collisson et al.

DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY (2000)